Reducing leukemia disparities in Latino children and teens
Official title: Reducing Disparities in Acute Leukemia (REDIAL) Consortium
Funded at Baylor College of Medicine · NIH-11420825 · Data updated 2026-11-12
A large, multi-project effort aims to understand why Latino children with acute lymphoblastic leukemia have worse outcomes and how to reduce those gaps.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 23, 2025 |
| Project end | August 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $2,372,294 |
| NIH project number | 5U54CA302464-02 |
| Project ID | NIH-11420825 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children and adolescents up to age 18 who have or are at risk for acute lymphoblastic leukemia, with a focus on Latino populations.
✕Less likely to help
Patients not belonging to Latino populations or those not undergoing ALL treatment may have limited direct benefit.
What this research studies
This program brings together several research teams to study biological factors and social determinants that affect treatment outcomes for Latino kids with ALL. It will examine how genetics, epigenetics, and drug responses contribute to toxicities and effectiveness of therapy, and how social factors influence access to and delivery of care. By identifying these disparities, the consortium seeks to guide more personalized treatments and supportive care to improve survival for affected patients. Participation may involve genetic analyses, clinical data, and collaboration across pediatric oncology centers. The effort represents a concerted, population-focused approach to narrowing race-related gaps in leukemia outcomes.
Why it matters
Potential benefit: If successful, this research could lead to tailored treatments and better supportive care that reduce side effects and improve survival for Latino children with ALL.
How similar studies have gone: Previous work shows race/ethnicity and pharmacogenomic differences can influence ALL outcomes, and this program builds on that by explicitly targeting disparities in Latino youth.
Where this research is happening
-
Baylor College of Medicine
Houston, United States Active
Researchers
- Principal investigator: Brown, Austin L — Baylor College of Medicine
- Study coordinator: Brown, Austin L
Related research
Other NIH-funded projects on the same topics.
-
Investigating a specific type of leukemia in children caused by genetic changes.
This study is looking at how certain proteins linked to leukemia affect kids and teens with high-risk blood cancers, and the researchers hope to find new ways to treat these conditions by learning more about how the disease works.
-
Genomic advances to improve outcomes in high-risk acute leukemia
A physician-scientist team is studying the genetic drivers of pediatric acute leukemia to find new ways to diagnose and treat it, with the goal of improving cure rates for kids.
-
Understanding and Targeting Extramedullary Acute Leukemia
A clinician-research team is studying myeloid sarcoma, a form of AML that forms solid tumors outside the bone marrow, to develop new treatments for patients.
-
Diversifying acute leukemia trial enrollment through multilevel approach
Aiming to broaden participation in acute leukemia trials by testing a multi-layer plan that addresses barriers for adults with AML.
-
Blocking menin to treat acute leukemias with high HOX gene activity
This work develops new drugs that block a protein called menin to help people with certain aggressive acute leukemias driven by HOX gene activation.
-
Predicting methotrexate-related brain side effects in children with ALL
This project works to predict which children and teens with acute lymphoblastic leukemia will develop methotrexate-related neurotoxicity using clinical signs and biological data.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.